Sign in

    Doug Lasalle • H.C. Wainwright & Co.

    Doug LaSalle is an Analyst at H.C. Wainwright & Co., specializing in equity research with a focus on the biotech and healthcare sectors. He is known to cover companies in the neuroscience and pharmaceuticals industries, including providing research coverage during Neurocrine Biosciences (NERV) earnings calls. While detailed performance metrics and external rankings are not publicly available, he has been actively involved in industry analysis and client communication for several years. Prior to joining H.C. Wainwright, there is no publicly reported record of his earlier professional affiliations, and his credentials or FINRA registrations have not been disclosed in available sources.

    Doug Lasalle's questions to SAGE Therapeutics Inc (SAGE) leadership

    Doug Lasalle's questions to SAGE Therapeutics Inc (SAGE) leadership • Q4 2024

    Question

    Doug Lasalle asked if management was surprised by the level of penetration with psychiatrists and what specific data from the upcoming SAGE-319 studies would provide confidence in the drug's activity beyond simple exposure.

    Answer

    CEO Barry Greene said they were not surprised, as the commercial strategy deliberately focuses on OB/GYNs who are at the front end of the patient journey. Regarding SAGE-319, CMO Laura Gault explained that the Phase 1 studies will use EEG to look for a specific brain activity signature that was observed in preclinical models. Confirming this differential signal in humans would provide evidence of the drug's unique mechanism of action.

    Ask Fintool Equity Research AI